The relationship between Tilray Brands and Europe seems to be strengthening as time goes by. The global cannabis industry leader has announced that FL Group, a division of Tilray Medical in Italy, has received the green light from the Italian Ministry of Health, giving it the authorization to import and distribute Tilray’s THC25 medical cannabis oral solution THC25 throughout the country.
Medical marijuana licensing in Italy is extremely limited, but Tilray Medical has been able to establish itself well enough to maintain strong operations. The division has an established national pharmaceutical distribution network with FL Group.
As a result of that partnership, the company is able to distribute Tilray’s THC25 medical cannabis oral solution. Patients throughout Italy can obtain prescriptions for Tilray and other medical cannabis products by consulting directly with their primary care physician.
“Expanding our approved authorization into Italy once again proves our commitment to be the most responsible, trusted and market leading cannabis company in the world with a portfolio of innovative and high-quality products that address the needs of the patients and consumers we serve,” said Denise Faltischek, Tilray’s CSO and Head of International Business. “We remain dedicated and focused on working with regulators across international markets to advocate for responsible cannabis regulations, best practices, and a reliable source of quality products.”
Tilray Medical has been making big moves over the past few months in order to meet the demand of all patients. It is a leading supplier of EU-GMP certified medical cannabis products in over 20 countries with a full portfolio of THC and CBD products. Tilray offers a variety of products that have been selected to ensure that patients can receive both the highest product quality and consistency when it comes to the supply of their medical cannabis products.